Marijuana oil may help with acne, eczema, and rosacea

Could CBD be useful in the battle versus resistant bacterial stress? The results from the University of Queensland in Australia recommend that it is possible. But prior to examining the research study in depth, it works to comprehend the development of the relationship between bacteria and prescription antibiotics.

Because the revolutionary discovery of penicillin by Alexander Fleming in 1928, prescription antibiotics have actually been a necessary tool in the battle versus bacteria and infections. And although we still use the exact same tested methods today, bacteria have actually evolved. When exposed to prescription antibiotics, certain bacteria, fungi and parasites have the ability to adjust and cancel the efficiency of the drug by developing resistance.

It’s worth explaining that antimicrobial resistance was likely to occur anyway, as the genetic code for bacteria modifications with time. However, it is thought that the overuse of prescription antibiotics is an essential factor that accelerates the development of resistant stress.

According to the World Health Organization, antimicrobial resistance “is an increasingly severe threat to worldwide public health that needs action in all sectors of government and in society.” This has led scientists to think outside package by trying to identify substances that could be beneficial in the battle versus harmful bacteria. One of these substances is cannabidiol (CBD), a cannabinoid found in Cannabis sativa.

Researchers are looking for new ways to attack infections and resistant bacteria.

Dr. Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and Senior Research Officer at the Institute for Molecular Bioscience at the University of Queensland, concluded that new earth CBD is effective versus Gram-positive bacteria. Stress of Gram-positive bacteria consist of Staphylococcus aureus (typical in skin infections) and Streptococcus pneumoniae (typical in bacterial pneumonia).

Dr. Blaskovich provided his findings at an annual conference of the American Society for Microbiology. In vitro samples of both types of gram-positive bacteria were treated with synthetic CBD. The results led Dr. Blaskovich to the conclusion that CBD works at levels comparable to those of prescription antibiotics vancomycin and daptomycin. He likewise found that CBD appeared to work against gram-positive stress of resistant bacteria, which many conventional prescription antibiotics are starting to stop working.

” In particular, the activity was picked versus the resistant stress of Staphylococcus aureus (MRSA, VISA, SARV), Streptococcus pneumoniae (MDR), and Enterococcus faecalis (ERV). Cannabidiol was bactericidal, had a low tendency to induce resistance and was active versus MRSA biofilms. “

The group likewise performed another research study using topical CBD to deal with a skin infection in mice. Again, although the results were positive, lakeshore CBD did not appear to get rid of the infection, but simply to minimize the variety of bacterial cells.

Could CBD become an antibiotic?

While it is simple to hail this work as a considerable advancement in the anti-bacterial capabilities of CBD, it is too soon to quit on penicillin.

Although it is thought that the efficiency of CBD might come from the method it attacks the biofilm surrounding bacterial cells, the authors are still uncertain of the system of action of CBD. They likewise did not hesitate to explain the imperfections of the research study. Dr. Blaskovich mentioned that because the results are in the preliminary stages, it is far too early for people to begin treating their CBD infections themselves.

The research study was likewise performed in vitro (outside the human body), and there is a risk that the results of clinical trials will not be the same. Numerous substances have actually revealed anti-bacterial effectiveness in petri dishes, but then failed at this crucial phase. It needs to likewise be mentioned that the two studies were carried out in partnership with Botanix Pharmaceuticals Ltd, a pharmaceutical company specializing in topical CBD products.

However, this research could be an essential step forward for CBD and the battle versus antimicrobial resistance. CBD continues to have a good security profile and is not considered hazardous even in big quantities. Thankfully, Dr. Blaskovich and his group plan to continue their research.

Scroll to top